Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H.

Vaccine. 2010 Aug 16;28(36):5794-802. doi: 10.1016/j.vaccine.2010.06.073. Epub 2010 Jul 4.

2.

DNA vaccines for cervical cancer: from bench to bedside.

Hung CF, Monie A, Alvarez RD, Wu TC.

Exp Mol Med. 2007 Dec 31;39(6):679-89. Review.

3.

Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Hung CF, Ma B, Monie A, Tsen SW, Wu TC.

Expert Opin Biol Ther. 2008 Apr;8(4):421-39. doi: 10.1517/14712598.8.4.421 . Review.

4.

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.

Barrios K, Celis E.

Cancer Immunol Immunother. 2012 Aug;61(8):1307-17. doi: 10.1007/s00262-012-1259-8. Epub 2012 Apr 22. Review.

5.
6.

Human papillomavirus vaccines for the treatment of cervical cancer.

Sin JI.

Expert Rev Vaccines. 2006 Dec;5(6):783-92. Review.

PMID:
17184217
7.

HPV Vaccines: today and in the Future.

Moscicki AB.

J Adolesc Health. 2008 Oct;43(4 Suppl):S26-40. doi: 10.1016/j.jadohealth.2008.07.010. Review.

8.
9.

ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.

Cory L, Chu C.

Hum Vaccin Immunother. 2014;10(11):3190-5. doi: 10.4161/hv.34378. Review.

10.

[Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].

Mora-García ML, Monroy-García A.

Rev Med Inst Mex Seguro Soc. 2015;53 Suppl 2:S206-11. Review. Spanish.

PMID:
26462518
11.

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.

12.

Emerging human papillomavirus vaccines.

Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC.

Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92. doi: 10.1517/14728214.2012.744393. Epub 2012 Nov 19. Review.

13.

Perspectives for preventive and therapeutic HPV vaccines.

Lin K, Doolan K, Hung CF, Wu TC.

J Formos Med Assoc. 2010 Jan;109(1):4-24. Review.

14.

HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Mariani L, Venuti A.

J Transl Med. 2010 Oct 27;8:105. doi: 10.1186/1479-5876-8-105. Review.

15.

Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.

Lee SJ, Yang A, Wu TC, Hung CF.

J Gynecol Oncol. 2016 Sep;27(5):e51. doi: 10.3802/jgo.2016.27.e51. Epub 2016 May 31. Review.

16.

Perspectives for therapeutic HPV vaccine development.

Yang A, Farmer E, Wu TC, Hung CF.

J Biomed Sci. 2016 Nov 4;23(1):75. Review.

17.

Current state in the development of candidate therapeutic HPV vaccines.

Yang A, Jeang J, Cheng K, Cheng T, Yang B, Wu TC, Hung CF.

Expert Rev Vaccines. 2016 Aug;15(8):989-1007. doi: 10.1586/14760584.2016.1157477. Epub 2016 Mar 7. Review.

18.

Immunotherapy for cervical cancer: Research status and clinical potential.

Su JH, Wu A, Scotney E, Ma B, Monie A, Hung CF, Wu TC.

BioDrugs. 2010 Apr 1;24(2):109-29. doi: 10.2165/11532810-000000000-00000. Review.

19.

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.

Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Saccà M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A.

Expert Rev Vaccines. 2016 Oct;15(10):1327-36. doi: 10.1080/14760584.2016.1176533. Epub 2016 May 9. Review.

20.

Antigen-specific immunotherapy of cervical and ovarian cancer.

Hung CF, Wu TC, Monie A, Roden R.

Immunol Rev. 2008 Apr;222:43-69. doi: 10.1111/j.1600-065X.2008.00622.x. Review.

Supplemental Content

Support Center